National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
Specialized Imaging Research Consortium™ (SIRC)
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NHL Guidelines Updated with Addition of Pralatrexate for Peripheral T-cell Lymphoma (PTCL)

The NCCN Clinical Practice Guidelines in Oncology™ for Non-Hodgkin’s Lymphomas have been updated. The updated NCCN Guidelines have added pralatrexate as a second-line therapy option for relapsed or refractory PTCL with a category 2A recommendation for patients who are not candidates for high dose therapy and a category 2B recommendation for patients who are candidates for high dose therapy.